> top > docs > PubMed:11850540 > annotations

PubMed:11850540 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 17-22 PR:P04626 denotes Her-2
T2 17-22 PR:000002082 denotes Her-2
T3 17-22 PR:Q03557 denotes Her-2
T4 17-22 PR:P34708 denotes Her-2
T5 17-22 PR:Q5AK64 denotes Her-2
T6 23-26 PR:P04626 denotes neu
T7 23-26 PR:000002082 denotes neu
T8 23-26 PR:000011145 denotes neu
T9 23-26 PR:P70424 denotes neu
T11 23-26 PR:000011149 denotes neu
T12 23-26 PR:O35657 denotes neu
T13 23-26 PR:P06494 denotes neu
T14 23-26 PR:P29503 denotes neu
T10 23-26 CHEBI:23995 denotes neu
T15 27-31 SO:0000704 denotes gene
T16 35-40 PR:P04626 denotes Her-2
T17 35-40 PR:000002082 denotes Her-2
T18 35-40 PR:Q03557 denotes Her-2
T19 35-40 PR:P34708 denotes Her-2
T20 35-40 PR:Q5AK64 denotes Her-2
T21 41-44 PR:P04626 denotes neu
T22 41-44 PR:000002082 denotes neu
T23 41-44 PR:000011145 denotes neu
T24 41-44 PR:P70424 denotes neu
T26 41-44 PR:000011149 denotes neu
T27 41-44 PR:O35657 denotes neu
T28 41-44 PR:P06494 denotes neu
T29 41-44 PR:P29503 denotes neu
T25 41-44 CHEBI:23995 denotes neu
T30 79-85 UBERON:0000310 denotes breast
T31 79-96 D001943 denotes breast carcinomas
T32 79-96 D001943 denotes breast carcinomas
T35 176-180 PR:000014829 denotes FISH
T36 176-180 PR:Q5TCZ1 denotes FISH
T37 220-225 PR:P04626 denotes Her-2
T38 220-225 PR:000002082 denotes Her-2
T39 220-225 PR:Q03557 denotes Her-2
T40 220-225 PR:P34708 denotes Her-2
T41 220-225 PR:Q5AK64 denotes Her-2
T42 226-229 PR:P04626 denotes neu
T43 226-229 PR:000002082 denotes neu
T44 226-229 PR:000011145 denotes neu
T45 226-229 PR:P70424 denotes neu
T47 226-229 PR:000011149 denotes neu
T48 226-229 PR:O35657 denotes neu
T49 226-229 PR:P06494 denotes neu
T50 226-229 PR:P29503 denotes neu
T46 226-229 CHEBI:23995 denotes neu
T51 233-239 UBERON:0000310 denotes breast
T52 233-249 D001943 denotes breast carcinoma
T53 233-249 D001943 denotes breast carcinoma
T56 291-298 D004194 denotes disease
T57 291-298 D004194 denotes disease
T58 346-350 UBERON:0003062 denotes node
T59 445-450 PR:P04626 denotes Her-2
T60 445-450 PR:000002082 denotes Her-2
T61 445-450 PR:Q03557 denotes Her-2
T62 445-450 PR:P34708 denotes Her-2
T63 445-450 PR:Q5AK64 denotes Her-2
T64 451-454 PR:P04626 denotes neu
T65 451-454 PR:000002082 denotes neu
T66 451-454 PR:000011145 denotes neu
T67 451-454 PR:P70424 denotes neu
T69 451-454 PR:000011149 denotes neu
T70 451-454 PR:O35657 denotes neu
T71 451-454 PR:P06494 denotes neu
T72 451-454 PR:P29503 denotes neu
T68 451-454 CHEBI:23995 denotes neu
T73 502-508 UBERON:0000310 denotes breast
T74 589-594 PR:P04626 denotes Her-2
T75 589-594 PR:000002082 denotes Her-2
T76 589-594 PR:Q03557 denotes Her-2
T77 589-594 PR:P34708 denotes Her-2
T78 589-594 PR:Q5AK64 denotes Her-2
T79 595-598 PR:P04626 denotes neu
T80 595-598 PR:000002082 denotes neu
T81 595-598 PR:000011145 denotes neu
T82 595-598 PR:P70424 denotes neu
T84 595-598 PR:000011149 denotes neu
T85 595-598 PR:O35657 denotes neu
T86 595-598 PR:P06494 denotes neu
T87 595-598 PR:P29503 denotes neu
T83 595-598 CHEBI:23995 denotes neu
T88 688-692 PR:000014829 denotes FISH
T89 688-692 PR:Q5TCZ1 denotes FISH
T90 720-725 PR:P04626 denotes Her-2
T91 720-725 PR:000002082 denotes Her-2
T92 720-725 PR:Q03557 denotes Her-2
T93 720-725 PR:P34708 denotes Her-2
T94 720-725 PR:Q5AK64 denotes Her-2
T95 726-729 PR:P04626 denotes neu
T96 726-729 PR:000002082 denotes neu
T97 726-729 PR:000011145 denotes neu
T98 726-729 PR:P70424 denotes neu
T100 726-729 PR:000011149 denotes neu
T101 726-729 PR:O35657 denotes neu
T102 726-729 PR:P06494 denotes neu
T103 726-729 PR:P29503 denotes neu
T99 726-729 CHEBI:23995 denotes neu
T104 754-771 D044584 denotes ductal carcinomas
T105 754-771 D044584 denotes ductal carcinomas
T108 815-820 PR:P04626 denotes Her-2
T109 815-820 PR:000002082 denotes Her-2
T110 815-820 PR:Q03557 denotes Her-2
T111 815-820 PR:P34708 denotes Her-2
T112 815-820 PR:Q5AK64 denotes Her-2
T113 821-824 PR:P04626 denotes neu
T114 821-824 PR:000002082 denotes neu
T115 821-824 PR:000011145 denotes neu
T116 821-824 PR:P70424 denotes neu
T118 821-824 PR:000011149 denotes neu
T119 821-824 PR:O35657 denotes neu
T120 821-824 PR:P06494 denotes neu
T121 821-824 PR:P29503 denotes neu
T117 821-824 CHEBI:23995 denotes neu
T122 825-833 GO:0019815 denotes antibody
T123 825-833 GO:0042571 denotes antibody
T124 825-833 GO:0019814 denotes antibody
T125 825-833 GO:0003823 denotes antibody
T126 868-879 D006965 denotes hyperplasia
T127 868-879 D006965 denotes hyperplasia
T128 886-913 D002285 denotes atypical ductal hyperplasia
T129 886-913 D002285 denotes atypical ductal hyperplasia
T132 915-918 P0A388 denotes ADH
T133 915-918 PR:P06525 denotes ADH
T134 915-918 Q8NXU1 denotes ADH
T135 915-918 Q6GBM4 denotes ADH
T136 915-918 Q47945 denotes ADH
T137 915-918 P0A389 denotes ADH
T138 915-918 Q5HRD6 denotes ADH
T139 915-918 P28036 denotes ADH
T140 915-918 P42327 denotes ADH
T141 915-918 PR:P00332 denotes ADH
T144 915-918 P81786 denotes ADH
T145 915-918 P18278 denotes ADH
T146 915-918 Q44002 denotes ADH
T147 915-918 Q7A742 denotes ADH
T148 915-918 O05542 denotes ADH
T149 915-918 Q2YSX0 denotes ADH
T150 915-918 Q6GJ63 denotes ADH
T151 915-918 PR:P00334 denotes ADH
T153 915-918 Q24857 denotes ADH
T154 915-918 Q8CQ56 denotes ADH
T155 915-918 Q2FJ31 denotes ADH
T156 915-918 Q2G0G1 denotes ADH
T157 915-918 PR:Q2G0G1 denotes ADH
T159 915-918 Q5HI63 denotes ADH
T160 915-918 Q99W07 denotes ADH
T161 915-918 Q04983 denotes ADH
T142 915-918 CHEBI:34543 denotes ADH
T158 915-918 CHEBI:9937 denotes ADH
T143 915-918 GO:0047636 denotes ADH
T152 915-918 GO:0004022 denotes ADH
T164 921-945 D002285 denotes ductal carcinoma in situ
T165 921-945 D002285 denotes ductal carcinoma in situ
T171 947-951 CVCL_5552 denotes DCIS
T170 947-951 D002285 denotes DCIS
T172 947-951 D002285 denotes DCIS
T173 985-990 D009369 denotes tumor
T174 985-990 D009369 denotes tumor
T175 1019-1030 D006416 denotes hematoxylin
T176 1019-1030 CHEBI:51686 denotes hematoxylin
T177 1019-1030 CHEBI:5601 denotes hematoxylin
T178 1019-1030 D006416 denotes hematoxylin
T179 1035-1040 1310593 denotes eosin
T180 1035-1040 D004801 denotes eosin
T181 1035-1040 D004801 denotes eosin
T182 1082-1091 D002277 denotes carcinoma
T183 1082-1091 D002277 denotes carcinoma
T184 1104-1109 UBERON:0002391 denotes lymph
T185 1117-1121 PR:Q54X95 denotes mets
T186 1117-1121 PR:P23395 denotes mets
T187 1117-1121 PR:P41162 denotes mets
T188 1117-1121 PR:Q8R4Z4 denotes mets
T189 1117-1121 PR:000007225 denotes mets
T190 1168-1178 D002277 denotes carcinomas
T191 1168-1178 D002277 denotes carcinomas
T192 1315-1319 PR:000014829 denotes FISH
T193 1315-1319 PR:Q5TCZ1 denotes FISH
T194 1378-1383 PR:P04626 denotes Her-2
T195 1378-1383 PR:000002082 denotes Her-2
T196 1378-1383 PR:Q03557 denotes Her-2
T197 1378-1383 PR:P34708 denotes Her-2
T198 1378-1383 PR:Q5AK64 denotes Her-2
T199 1384-1387 PR:P04626 denotes neu
T200 1384-1387 PR:000002082 denotes neu
T201 1384-1387 PR:000011145 denotes neu
T202 1384-1387 PR:P70424 denotes neu
T204 1384-1387 PR:000011149 denotes neu
T205 1384-1387 PR:O35657 denotes neu
T206 1384-1387 PR:P06494 denotes neu
T207 1384-1387 PR:P29503 denotes neu
T203 1384-1387 CHEBI:23995 denotes neu
T208 1391-1394 P0A388 denotes ADH
T209 1391-1394 PR:P06525 denotes ADH
T210 1391-1394 Q8NXU1 denotes ADH
T211 1391-1394 Q6GBM4 denotes ADH
T212 1391-1394 Q47945 denotes ADH
T213 1391-1394 P0A389 denotes ADH
T214 1391-1394 Q5HRD6 denotes ADH
T215 1391-1394 P28036 denotes ADH
T216 1391-1394 P42327 denotes ADH
T217 1391-1394 PR:P00332 denotes ADH
T220 1391-1394 P81786 denotes ADH
T221 1391-1394 P18278 denotes ADH
T222 1391-1394 Q44002 denotes ADH
T223 1391-1394 Q7A742 denotes ADH
T224 1391-1394 O05542 denotes ADH
T225 1391-1394 Q2YSX0 denotes ADH
T226 1391-1394 Q6GJ63 denotes ADH
T227 1391-1394 PR:P00334 denotes ADH
T229 1391-1394 Q24857 denotes ADH
T230 1391-1394 Q8CQ56 denotes ADH
T231 1391-1394 Q2FJ31 denotes ADH
T232 1391-1394 Q2G0G1 denotes ADH
T233 1391-1394 PR:Q2G0G1 denotes ADH
T235 1391-1394 Q5HI63 denotes ADH
T236 1391-1394 Q99W07 denotes ADH
T237 1391-1394 Q04983 denotes ADH
T218 1391-1394 CHEBI:34543 denotes ADH
T234 1391-1394 CHEBI:9937 denotes ADH
T219 1391-1394 GO:0047636 denotes ADH
T228 1391-1394 GO:0004022 denotes ADH
T238 1434-1437 P0A388 denotes ADH
T239 1434-1437 PR:P06525 denotes ADH
T240 1434-1437 Q8NXU1 denotes ADH
T241 1434-1437 Q6GBM4 denotes ADH
T242 1434-1437 Q47945 denotes ADH
T243 1434-1437 P0A389 denotes ADH
T244 1434-1437 Q5HRD6 denotes ADH
T245 1434-1437 P28036 denotes ADH
T246 1434-1437 P42327 denotes ADH
T247 1434-1437 PR:P00332 denotes ADH
T250 1434-1437 P81786 denotes ADH
T251 1434-1437 P18278 denotes ADH
T252 1434-1437 Q44002 denotes ADH
T253 1434-1437 Q7A742 denotes ADH
T254 1434-1437 O05542 denotes ADH
T255 1434-1437 Q2YSX0 denotes ADH
T256 1434-1437 Q6GJ63 denotes ADH
T257 1434-1437 PR:P00334 denotes ADH
T259 1434-1437 Q24857 denotes ADH
T260 1434-1437 Q8CQ56 denotes ADH
T261 1434-1437 Q2FJ31 denotes ADH
T262 1434-1437 Q2G0G1 denotes ADH
T263 1434-1437 PR:Q2G0G1 denotes ADH
T265 1434-1437 Q5HI63 denotes ADH
T266 1434-1437 Q99W07 denotes ADH
T267 1434-1437 Q04983 denotes ADH
T248 1434-1437 CHEBI:34543 denotes ADH
T264 1434-1437 CHEBI:9937 denotes ADH
T249 1434-1437 GO:0047636 denotes ADH
T258 1434-1437 GO:0004022 denotes ADH
T269 1446-1450 CVCL_5552 denotes DCIS
T268 1446-1450 D002285 denotes DCIS
T270 1446-1450 D002285 denotes DCIS
T272 1475-1479 CVCL_5552 denotes DCIS
T271 1475-1479 D002285 denotes DCIS
T273 1475-1479 D002285 denotes DCIS
T274 1524-1541 UBERON:0034969 denotes ductal epithelium
T276 1612-1617 UBERON:0002391 denotes lymph
T277 1663-1668 PR:P04626 denotes Her-2
T278 1663-1668 PR:000002082 denotes Her-2
T279 1663-1668 PR:Q03557 denotes Her-2
T280 1663-1668 PR:P34708 denotes Her-2
T281 1663-1668 PR:Q5AK64 denotes Her-2
T282 1669-1672 PR:P04626 denotes neu
T283 1669-1672 PR:000002082 denotes neu
T284 1669-1672 PR:000011145 denotes neu
T285 1669-1672 PR:P70424 denotes neu
T287 1669-1672 PR:000011149 denotes neu
T288 1669-1672 PR:O35657 denotes neu
T289 1669-1672 PR:P06494 denotes neu
T290 1669-1672 PR:P29503 denotes neu
T286 1669-1672 CHEBI:23995 denotes neu
T291 1703-1712 D002277 denotes carcinoma
T292 1703-1712 D002277 denotes carcinoma
T293 1757-1767 D009362 denotes metastases
T294 1757-1767 D009362 denotes metastases
T295 1859-1862 P0A388 denotes ADH
T296 1859-1862 PR:P06525 denotes ADH
T297 1859-1862 Q8NXU1 denotes ADH
T298 1859-1862 Q6GBM4 denotes ADH
T299 1859-1862 Q47945 denotes ADH
T300 1859-1862 P0A389 denotes ADH
T301 1859-1862 Q5HRD6 denotes ADH
T302 1859-1862 P28036 denotes ADH
T303 1859-1862 P42327 denotes ADH
T304 1859-1862 PR:P00332 denotes ADH
T307 1859-1862 P81786 denotes ADH
T308 1859-1862 P18278 denotes ADH
T309 1859-1862 Q44002 denotes ADH
T310 1859-1862 Q7A742 denotes ADH
T311 1859-1862 O05542 denotes ADH
T312 1859-1862 Q2YSX0 denotes ADH
T313 1859-1862 Q6GJ63 denotes ADH
T314 1859-1862 PR:P00334 denotes ADH
T316 1859-1862 Q24857 denotes ADH
T317 1859-1862 Q8CQ56 denotes ADH
T318 1859-1862 Q2FJ31 denotes ADH
T319 1859-1862 Q2G0G1 denotes ADH
T320 1859-1862 PR:Q2G0G1 denotes ADH
T322 1859-1862 Q5HI63 denotes ADH
T323 1859-1862 Q99W07 denotes ADH
T324 1859-1862 Q04983 denotes ADH
T305 1859-1862 CHEBI:34543 denotes ADH
T321 1859-1862 CHEBI:9937 denotes ADH
T306 1859-1862 GO:0047636 denotes ADH
T315 1859-1862 GO:0004022 denotes ADH
T326 1866-1870 CVCL_5552 denotes DCIS
T325 1866-1870 D002285 denotes DCIS
T327 1866-1870 D002285 denotes DCIS
T328 1883-1892 D002277 denotes carcinoma
T329 1883-1892 D002277 denotes carcinoma
T330 1902-1905 P0A388 denotes ADH
T331 1902-1905 PR:P06525 denotes ADH
T332 1902-1905 Q8NXU1 denotes ADH
T333 1902-1905 Q6GBM4 denotes ADH
T334 1902-1905 Q47945 denotes ADH
T335 1902-1905 P0A389 denotes ADH
T336 1902-1905 Q5HRD6 denotes ADH
T337 1902-1905 P28036 denotes ADH
T338 1902-1905 P42327 denotes ADH
T339 1902-1905 PR:P00332 denotes ADH
T342 1902-1905 P81786 denotes ADH
T343 1902-1905 P18278 denotes ADH
T344 1902-1905 Q44002 denotes ADH
T345 1902-1905 Q7A742 denotes ADH
T346 1902-1905 O05542 denotes ADH
T347 1902-1905 Q2YSX0 denotes ADH
T348 1902-1905 Q6GJ63 denotes ADH
T349 1902-1905 PR:P00334 denotes ADH
T351 1902-1905 Q24857 denotes ADH
T352 1902-1905 Q8CQ56 denotes ADH
T353 1902-1905 Q2FJ31 denotes ADH
T354 1902-1905 Q2G0G1 denotes ADH
T355 1902-1905 PR:Q2G0G1 denotes ADH
T357 1902-1905 Q5HI63 denotes ADH
T358 1902-1905 Q99W07 denotes ADH
T359 1902-1905 Q04983 denotes ADH
T340 1902-1905 CHEBI:34543 denotes ADH
T356 1902-1905 CHEBI:9937 denotes ADH
T341 1902-1905 GO:0047636 denotes ADH
T350 1902-1905 GO:0004022 denotes ADH
T361 1913-1917 CVCL_5552 denotes DCIS
T360 1913-1917 D002285 denotes DCIS
T362 1913-1917 D002285 denotes DCIS
T364 1927-1931 CVCL_5552 denotes DCIS
T363 1927-1931 D002285 denotes DCIS
T365 1927-1931 D002285 denotes DCIS
T366 2025-2032 D009369 denotes cancers
T367 2025-2032 D009369 denotes cancers
T368 2058-2068 D009362 denotes metastases
T369 2058-2068 D009362 denotes metastases
T370 2097-2102 PR:P04626 denotes Her-2
T371 2097-2102 PR:000002082 denotes Her-2
T372 2097-2102 PR:Q03557 denotes Her-2
T373 2097-2102 PR:P34708 denotes Her-2
T374 2097-2102 PR:Q5AK64 denotes Her-2
T375 2103-2106 PR:P04626 denotes neu
T376 2103-2106 PR:000002082 denotes neu
T377 2103-2106 PR:000011145 denotes neu
T378 2103-2106 PR:P70424 denotes neu
T380 2103-2106 PR:000011149 denotes neu
T381 2103-2106 PR:O35657 denotes neu
T382 2103-2106 PR:P06494 denotes neu
T383 2103-2106 PR:P29503 denotes neu
T379 2103-2106 CHEBI:23995 denotes neu
T384 2144-2149 PR:P04626 denotes Her-2
T385 2144-2149 PR:000002082 denotes Her-2
T386 2144-2149 PR:Q03557 denotes Her-2
T387 2144-2149 PR:P34708 denotes Her-2
T388 2144-2149 PR:Q5AK64 denotes Her-2
T389 2150-2153 PR:P04626 denotes neu
T390 2150-2153 PR:000002082 denotes neu
T391 2150-2153 PR:000011145 denotes neu
T392 2150-2153 PR:P70424 denotes neu
T394 2150-2153 PR:000011149 denotes neu
T395 2150-2153 PR:O35657 denotes neu
T396 2150-2153 PR:P06494 denotes neu
T397 2150-2153 PR:P29503 denotes neu
T393 2150-2153 CHEBI:23995 denotes neu
T398 2186-2196 D002277 denotes carcinomas
T399 2186-2196 D002277 denotes carcinomas
T400 2240-2245 PR:P04626 denotes Her-2
T401 2240-2245 PR:000002082 denotes Her-2
T402 2240-2245 PR:Q03557 denotes Her-2
T403 2240-2245 PR:P34708 denotes Her-2
T404 2240-2245 PR:Q5AK64 denotes Her-2
T405 2246-2249 PR:P04626 denotes neu
T406 2246-2249 PR:000002082 denotes neu
T407 2246-2249 PR:000011145 denotes neu
T408 2246-2249 PR:P70424 denotes neu
T410 2246-2249 PR:000011149 denotes neu
T411 2246-2249 PR:O35657 denotes neu
T412 2246-2249 PR:P06494 denotes neu
T413 2246-2249 PR:P29503 denotes neu
T409 2246-2249 CHEBI:23995 denotes neu
T414 2250-2258 GO:0019815 denotes antibody
T415 2250-2258 GO:0042571 denotes antibody
T416 2250-2258 GO:0019814 denotes antibody
T417 2250-2258 GO:0003823 denotes antibody
T418 2423-2428 D009369 denotes tumor
T419 2423-2428 D009369 denotes tumor
T420 2452-2462 D009362 denotes metastasis
T421 2452-2462 D009362 denotes metastasis
T422 2526-2535 D002277 denotes carcinoma
T423 2526-2535 D002277 denotes carcinoma
T425 2581-2588 D009369 denotes cancers
T426 2581-2588 D009369 denotes cancers
T427 2595-2599 PR:000014829 denotes FISH
T428 2595-2599 PR:Q5TCZ1 denotes FISH
T429 2638-2643 PR:P04626 denotes Her-2
T430 2638-2643 PR:000002082 denotes Her-2
T431 2638-2643 PR:Q03557 denotes Her-2
T432 2638-2643 PR:P34708 denotes Her-2
T433 2638-2643 PR:Q5AK64 denotes Her-2
T434 2644-2647 PR:P04626 denotes neu
T435 2644-2647 PR:000002082 denotes neu
T436 2644-2647 PR:000011145 denotes neu
T437 2644-2647 PR:P70424 denotes neu
T439 2644-2647 PR:000011149 denotes neu
T440 2644-2647 PR:O35657 denotes neu
T441 2644-2647 PR:P06494 denotes neu
T442 2644-2647 PR:P29503 denotes neu
T438 2644-2647 CHEBI:23995 denotes neu
T443 2687-2694 D004194 denotes disease
T444 2687-2694 D004194 denotes disease
T445 2709-2712 P0A388 denotes ADH
T446 2709-2712 PR:P06525 denotes ADH
T447 2709-2712 Q8NXU1 denotes ADH
T448 2709-2712 Q6GBM4 denotes ADH
T449 2709-2712 Q47945 denotes ADH
T450 2709-2712 P0A389 denotes ADH
T451 2709-2712 Q5HRD6 denotes ADH
T452 2709-2712 P28036 denotes ADH
T453 2709-2712 P42327 denotes ADH
T454 2709-2712 PR:P00332 denotes ADH
T457 2709-2712 P81786 denotes ADH
T458 2709-2712 P18278 denotes ADH
T459 2709-2712 Q44002 denotes ADH
T460 2709-2712 Q7A742 denotes ADH
T461 2709-2712 O05542 denotes ADH
T462 2709-2712 Q2YSX0 denotes ADH
T463 2709-2712 Q6GJ63 denotes ADH
T464 2709-2712 PR:P00334 denotes ADH
T466 2709-2712 Q24857 denotes ADH
T467 2709-2712 Q8CQ56 denotes ADH
T468 2709-2712 Q2FJ31 denotes ADH
T469 2709-2712 Q2G0G1 denotes ADH
T470 2709-2712 PR:Q2G0G1 denotes ADH
T472 2709-2712 Q5HI63 denotes ADH
T473 2709-2712 Q99W07 denotes ADH
T474 2709-2712 Q04983 denotes ADH
T455 2709-2712 CHEBI:34543 denotes ADH
T471 2709-2712 CHEBI:9937 denotes ADH
T456 2709-2712 GO:0047636 denotes ADH
T465 2709-2712 GO:0004022 denotes ADH
T475 2768-2771 P0A388 denotes ADH
T476 2768-2771 PR:P06525 denotes ADH
T477 2768-2771 Q8NXU1 denotes ADH
T478 2768-2771 Q6GBM4 denotes ADH
T479 2768-2771 Q47945 denotes ADH
T480 2768-2771 P0A389 denotes ADH
T481 2768-2771 Q5HRD6 denotes ADH
T482 2768-2771 P28036 denotes ADH
T483 2768-2771 P42327 denotes ADH
T484 2768-2771 PR:P00332 denotes ADH
T487 2768-2771 P81786 denotes ADH
T488 2768-2771 P18278 denotes ADH
T489 2768-2771 Q44002 denotes ADH
T490 2768-2771 Q7A742 denotes ADH
T491 2768-2771 O05542 denotes ADH
T492 2768-2771 Q2YSX0 denotes ADH
T493 2768-2771 Q6GJ63 denotes ADH
T494 2768-2771 PR:P00334 denotes ADH
T496 2768-2771 Q24857 denotes ADH
T497 2768-2771 Q8CQ56 denotes ADH
T498 2768-2771 Q2FJ31 denotes ADH
T499 2768-2771 Q2G0G1 denotes ADH
T500 2768-2771 PR:Q2G0G1 denotes ADH
T502 2768-2771 Q5HI63 denotes ADH
T503 2768-2771 Q99W07 denotes ADH
T504 2768-2771 Q04983 denotes ADH
T485 2768-2771 CHEBI:34543 denotes ADH
T501 2768-2771 CHEBI:9937 denotes ADH
T486 2768-2771 GO:0047636 denotes ADH
T495 2768-2771 GO:0004022 denotes ADH
T506 2775-2779 CVCL_5552 denotes DCIS
T505 2775-2779 D002285 denotes DCIS
T507 2775-2779 D002285 denotes DCIS
T508 2795-2800 PR:P04626 denotes Her-2
T509 2795-2800 PR:000002082 denotes Her-2
T510 2795-2800 PR:Q03557 denotes Her-2
T511 2795-2800 PR:P34708 denotes Her-2
T512 2795-2800 PR:Q5AK64 denotes Her-2
T513 2801-2804 PR:P04626 denotes neu
T514 2801-2804 PR:000002082 denotes neu
T515 2801-2804 PR:000011145 denotes neu
T516 2801-2804 PR:P70424 denotes neu
T518 2801-2804 PR:000011149 denotes neu
T519 2801-2804 PR:O35657 denotes neu
T520 2801-2804 PR:P06494 denotes neu
T521 2801-2804 PR:P29503 denotes neu
T517 2801-2804 CHEBI:23995 denotes neu
T522 2858-2867 D002277 denotes carcinoma
T523 2858-2867 D002277 denotes carcinoma
T524 2916-2926 D009362 denotes metastasis
T525 2916-2926 D009362 denotes metastasis
T526 2967-2972 PR:P04626 denotes Her-2
T527 2967-2972 PR:000002082 denotes Her-2
T528 2967-2972 PR:Q03557 denotes Her-2
T529 2967-2972 PR:P34708 denotes Her-2
T530 2967-2972 PR:Q5AK64 denotes Her-2
T531 2973-2976 PR:P04626 denotes neu
T532 2973-2976 PR:000002082 denotes neu
T533 2973-2976 PR:000011145 denotes neu
T534 2973-2976 PR:P70424 denotes neu
T536 2973-2976 PR:000011149 denotes neu
T537 2973-2976 PR:O35657 denotes neu
T538 2973-2976 PR:P06494 denotes neu
T539 2973-2976 PR:P29503 denotes neu
T535 2973-2976 CHEBI:23995 denotes neu
T540 3024-3030 UBERON:0000310 denotes breast
T541 3031-3042 GO:0007048 denotes oncogenesis
T542 3031-3042 D063646 denotes oncogenesis
T543 3031-3042 D063646 denotes oncogenesis
T544 3079-3085 UBERON:0000310 denotes breast
T545 3086-3093 D009369 denotes cancers
T546 3086-3093 D009369 denotes cancers

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-202 DRI_Background denotes Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
T2 203-383 DRI_Background denotes Amplification of Her-2/neu in breast carcinoma is associated with poor prognosis, short disease-free interval, and short survival time in both node-negative and -positive patients.
T3 384-517 DRI_Challenge denotes Little is known about the starting point of amplification of Her-2/neu and how it progresses from benign to malignant breast lesions.
T4 518-694 DRI_Approach denotes We attempted to address these questions by evaluating amplification of Her-2/neu in benign, premalignant, and malignant lesions using fluorescence in situ hybridization (FISH).
T5 695-1152 DRI_Background denotes Twenty-six patients with Her-2/neu-overexpressing invasive ductal carcinomas (as judged by strong immunoreactivity with Her-2/neu antibody) and coexisting lesions of ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) in the vicinity of the invasive tumor (as judged by review of the hematoxylin and eosin-stained sections), as well as metastatic carcinoma in axillary lymph nodes (mets) were selected for this study.
T6 1153-1338 DRI_Background denotes In the primary carcinomas, a close relationship was present between overexpression as detected by immunohistochemistry (IHC) and amplification as demonstrated by FISH (85% concordance).
T7 1339-1480 DRI_Background denotes Among these patients, amplification of Her-2/neu in ADH was demonstrated in 7 of 13 cases with ADH, and in DCIS, in 21 of 22 cases with DCIS.
T8 1481-1542 DRI_Background denotes There was no amplification in DH or normal ductal epithelium.
T9 1543-1713 DRI_Outcome denotes Significantly, in all 12 patients with synchronous positive axillary lymph nodes, there was concordant amplification of Her-2/neu in the primary and metastatic carcinoma.
T10 1714-1822 DRI_Outcome denotes Amplification was consistent in multifocal metastases, despite morphological heterogeneity in some patients.
T11 1823-2078 DRI_Outcome denotes Amplification ratios increased from ADH to DCIS to invasive carcinoma (P <.01, ADH versus DCIS; P <.05, DCIS versus invasive cancer), but there was no difference in amplification ratios between primary cancers and synchronous axillary metastases (P >.05).
T12 2079-2260 DRI_Approach denotes We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody).
T13 2261-2377 DRI_Outcome denotes Three showed amplification in both primary and metastatic lesions, with a low amplification ratio (approximately 2).
T14 2378-2463 DRI_Outcome denotes One patient had amplification in the primary tumor but not in an axillary metastasis.
T15 2464-2589 DRI_Background denotes Two patients exhibited slight amplification in the metastatic carcinoma (ratios 1.6 and 2), but not in their primary cancers.
T16 2590-2780 DRI_Outcome denotes This FISH study indicates that amplification of Her-2/neu can emerge de novo in any stage of the disease process, from ADH to metastatic lesions, but most often appears first in ADH or DCIS.
T17 2781-2927 DRI_Outcome denotes The degree of Her-2/neu amplification increases with progression to invasive carcinoma, there being no further increase in synchronous metastasis.
T18 2928-3107 DRI_Outcome denotes Our data suggest that amplification of Her-2/neu appears to be mainly involved in initiation of breast oncogenesis and that its role in progression of breast cancers is uncertain.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 203-383 DRI_Background denotes Amplification of Her-2/neu in breast carcinoma is associated with poor prognosis, short disease-free interval, and short survival time in both node-negative and -positive patients.
T2 384-517 DRI_Challenge denotes Little is known about the starting point of amplification of Her-2/neu and how it progresses from benign to malignant breast lesions.
T3 518-694 DRI_Approach denotes We attempted to address these questions by evaluating amplification of Her-2/neu in benign, premalignant, and malignant lesions using fluorescence in situ hybridization (FISH).
T4 695-1152 DRI_Background denotes Twenty-six patients with Her-2/neu-overexpressing invasive ductal carcinomas (as judged by strong immunoreactivity with Her-2/neu antibody) and coexisting lesions of ductal hyperplasia (DH), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) in the vicinity of the invasive tumor (as judged by review of the hematoxylin and eosin-stained sections), as well as metastatic carcinoma in axillary lymph nodes (mets) were selected for this study.
T5 1153-1338 DRI_Background denotes In the primary carcinomas, a close relationship was present between overexpression as detected by immunohistochemistry (IHC) and amplification as demonstrated by FISH (85% concordance).
T6 1339-1480 DRI_Background denotes Among these patients, amplification of Her-2/neu in ADH was demonstrated in 7 of 13 cases with ADH, and in DCIS, in 21 of 22 cases with DCIS.
T7 1481-1542 DRI_Background denotes There was no amplification in DH or normal ductal epithelium.
T8 1543-1713 DRI_Outcome denotes Significantly, in all 12 patients with synchronous positive axillary lymph nodes, there was concordant amplification of Her-2/neu in the primary and metastatic carcinoma.
T9 1714-1822 DRI_Outcome denotes Amplification was consistent in multifocal metastases, despite morphological heterogeneity in some patients.
T10 1823-2078 DRI_Outcome denotes Amplification ratios increased from ADH to DCIS to invasive carcinoma (P <.01, ADH versus DCIS; P <.05, DCIS versus invasive cancer), but there was no difference in amplification ratios between primary cancers and synchronous axillary metastases (P >.05).
T11 2079-2260 DRI_Approach denotes We also evaluated Her-2/neu amplification in 21 patients without Her-2/neu overexpression in their primary carcinomas (as judged by absent immunoreactivity with Her-2/neu antibody).
T12 2261-2377 DRI_Outcome denotes Three showed amplification in both primary and metastatic lesions, with a low amplification ratio (approximately 2).
T13 2378-2463 DRI_Outcome denotes One patient had amplification in the primary tumor but not in an axillary metastasis.
T14 2464-2589 DRI_Background denotes Two patients exhibited slight amplification in the metastatic carcinoma (ratios 1.6 and 2), but not in their primary cancers.
T15 2590-2780 DRI_Outcome denotes This FISH study indicates that amplification of Her-2/neu can emerge de novo in any stage of the disease process, from ADH to metastatic lesions, but most often appears first in ADH or DCIS.
T16 2781-2927 DRI_Outcome denotes The degree of Her-2/neu amplification increases with progression to invasive carcinoma, there being no further increase in synchronous metastasis.
T17 2928-3107 DRI_Outcome denotes Our data suggest that amplification of Her-2/neu appears to be mainly involved in initiation of breast oncogenesis and that its role in progression of breast cancers is uncertain.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
11850540-0#17#26#gene2064 17-26 gene2064 denotes Her-2/neu
11850540-0#35#44#gene2064 35-44 gene2064 denotes Her-2/neu
11850540-0#79#96#diseaseC0678222 79-96 diseaseC0678222 denotes breast carcinomas
11850540-15#48#57#gene2064 2638-2647 gene2064 denotes Her-2/neu
11850540-15#119#122#diseaseC1332347 2709-2712 diseaseC1332347 denotes ADH
11850540-15#178#181#diseaseC1332347 2768-2771 diseaseC1332347 denotes ADH
11850540-15#185#189#diseaseC0007124 2775-2779 diseaseC0007124 denotes DCIS
11850540-16#14#23#gene2064 2795-2804 gene2064 denotes Her-2/neu
11850540-16#14#23#gene2064 2795-2804 gene2064 denotes Her-2/neu
11850540-16#135#145#diseaseC0027627 2916-2926 diseaseC0027627 denotes metastasis
11850540-16#68#86#diseaseC1334274 2849-2867 diseaseC1334274 denotes invasive carcinoma
11850540-17#39#48#gene2064 2967-2976 gene2064 denotes Her-2/neu
11850540-17#103#114#diseaseC0596263 3031-3042 diseaseC0596263 denotes oncogenesis
11850540-17#151#165#diseaseC0006142 3079-3093 diseaseC0006142 denotes breast cancers
11850540-4#25#34#gene2064 720-729 gene2064 denotes Her-2/neu
11850540-4#120#129#gene2064 815-824 gene2064 denotes Her-2/neu
11850540-4#59#76#diseaseC1176475 754-771 diseaseC1176475 denotes ductal carcinomas
11850540-8#120#129#gene2064 1663-1672 gene2064 denotes Her-2/neu
11850540-8#149#169#diseaseC1384494 1692-1712 diseaseC1384494 denotes metastatic carcinoma
17#26#gene206479#96#diseaseC0678222 11850540-0#17#26#gene2064 11850540-0#79#96#diseaseC0678222 associated_with Her-2/neu,breast carcinomas
35#44#gene206479#96#diseaseC0678222 11850540-0#35#44#gene2064 11850540-0#79#96#diseaseC0678222 associated_with Her-2/neu,breast carcinomas
48#57#gene2064119#122#diseaseC1332347 11850540-15#48#57#gene2064 11850540-15#119#122#diseaseC1332347 associated_with Her-2/neu,ADH
48#57#gene2064178#181#diseaseC1332347 11850540-15#48#57#gene2064 11850540-15#178#181#diseaseC1332347 associated_with Her-2/neu,ADH
48#57#gene2064185#189#diseaseC0007124 11850540-15#48#57#gene2064 11850540-15#185#189#diseaseC0007124 associated_with Her-2/neu,DCIS
14#23#gene2064135#145#diseaseC0027627 11850540-16#14#23#gene2064 11850540-16#135#145#diseaseC0027627 associated_with Her-2/neu,metastasis
14#23#gene206468#86#diseaseC1334274 11850540-16#14#23#gene2064 11850540-16#68#86#diseaseC1334274 associated_with Her-2/neu,invasive carcinoma
14#23#gene2064135#145#diseaseC0027627 11850540-16#14#23#gene2064 11850540-16#135#145#diseaseC0027627 associated_with Her-2/neu,metastasis
14#23#gene206468#86#diseaseC1334274 11850540-16#14#23#gene2064 11850540-16#68#86#diseaseC1334274 associated_with Her-2/neu,invasive carcinoma
39#48#gene2064103#114#diseaseC0596263 11850540-17#39#48#gene2064 11850540-17#103#114#diseaseC0596263 associated_with Her-2/neu,oncogenesis
39#48#gene2064151#165#diseaseC0006142 11850540-17#39#48#gene2064 11850540-17#151#165#diseaseC0006142 associated_with Her-2/neu,breast cancers
25#34#gene206459#76#diseaseC1176475 11850540-4#25#34#gene2064 11850540-4#59#76#diseaseC1176475 associated_with Her-2/neu,ductal carcinomas
120#129#gene206459#76#diseaseC1176475 11850540-4#120#129#gene2064 11850540-4#59#76#diseaseC1176475 associated_with Her-2/neu,ductal carcinomas
120#129#gene2064149#169#diseaseC1384494 11850540-8#120#129#gene2064 11850540-8#149#169#diseaseC1384494 associated_with Her-2/neu,metastatic carcinoma

DisGeNET

Id Subject Object Predicate Lexical cue
T0 220-229 gene:2064 denotes Her-2/neu
T1 233-249 disease:C0006142 denotes breast carcinoma
T2 220-229 gene:2064 denotes Her-2/neu
T3 233-249 disease:C0678222 denotes breast carcinoma
R1 T0 T1 associated_with Her-2/neu,breast carcinoma
R2 T2 T3 associated_with Her-2/neu,breast carcinoma